Activated protein C (Xigris®) treatment in sepsis: A drug in trouble

Acta Anaesthesiologica Scandinavica

Volumn 50, Issue 8, 2006, Pages 907-910

  Gardlund B ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Activated Protein C; APC; Drotrecogin alfa; rhAPC; Sepsis; Septic shock; Severe sepsis; Xigris

Indexed keywords

DROTRECOGIN; HYPERTENSIVE AGENT;

ARTICLE; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; HIGH RISK PATIENT; HUMAN; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; SEPSIS;

ANTI-INFECTIVE AGENTS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HUMANS; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS; TREATMENT FAILURE;

EID: 33747637759     PISSN: 00015172     EISSN: 13996576     Source Type: Journal    
DOI: 10.1111/j.1399-6576.2006.01086.x     Document Type: Article

References (10)

1. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
2. U.S. Food and Drug Administration. FDA clinical review drotrecogin alfa (activated) [recombinant human activated protein C (rhAPC)] Xigris, bla 125029/0, approved 21 November 2001 [WWW document]. URL http://www.fda.gov/cder/ biologics/review/droteli112101r1.htm [accessed 29 April 2006].
3. Abraham E, Laterre P-F, Garg R, Levy H, Talwar D, Trzaskoma BL et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353: 1332-41.
4. DeMets DL, Fleming TR, Whitley RJ, Childress JF, Ellenberg SS, Foulkes M et al. The data and safety monitoring board and acquired immune deficiency syndrome (AIDS) clinical trials. Controlled Clin Trials 1995; 16: 408-21.
5. Bernard GR, Macias WL, Joyce DE, Williams MD, Bailey J, Vincent J-L. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit Care 2003; 7: 155-63.
6. U.S. Food and Drug Administration. 2005 safety alert: Xigris [drotrecogin alfa (activated)]. Re: Discontinuation of study F1K-MC-EVBP, investigation of the efficacy and safety of drotrecogin alfa (activated) in pediatric severe sepsis [WWW document]. http://www.fda.gov/medwatch/safety/2005/xigris_dearHCP_4- 21-05.htm [accessed 29 April 2006].
7. Eichacker PQ, Natanson C. Recombinant human activated protein C in sepsis: Inconsistent trial results, an unclear mechanism of action, and safety concerns resulting in labeling restrictions and the need for phase IV trials. Crit Care Med 2003; 31 (Suppl. 1): S94-S96.
8. Eichacker PQ, Danner RL, Suffredini AF, Cui X, Natanson C. Reassessing recombinant human activated protein C for sepsis: Time for a new randomized controlled trial. Crit Care Med 2005; 33: 2426-8.
9. Mackenzie AF. Activated protein C: do more survive? Intensive Care Med 2005; 31: 1624-6.
10. Wiedermann CJ, Kaneider NC. A meta-analysis of controlled trials of recombinant human activated protein C therapy in patients with sepsis. BMC Emerg Med 2005; 5: 7 [available at. http:/www.biomedcentral.com/1471-227X/5/7 accessed April 29 2006].